Documents in the NTIS Technical Reports collection are the results of federally funded research. They are directly submitted to or collected by NTIS from Federal agencies for permanent accessibility to industry, academia and the public.  Before purchasing from NTIS, you may want to check for free access from (1) the issuing organization's website; (2) the U.S. Government Printing Office's Federal Digital System website http://www.gpo.gov/fdsys; (3) the federal government Internet portal USA.gov; or (4) a web search conducted using a commercial search engine such as http://www.google.com.
Accession Number ADA564543
Title Translational Research for Muscular Dystrophy.
Publication Date May 2012
Media Count 12p
Personal Author G. A. Cox
Abstract The goal of this work is to increase the availability of critical mouse models of human muscular dystrophy (MD) for both hypothesis testing and preclinical therapy development. Our multi-disciplinary team from The Jackson Laboratory (JAX) and the Children s National Medical Center (CNMC) has expertise in MD, repository management, mouse models, and preclinical testing. At JAX, Drs. Lutz and Cox have established the MD Repository (Aim1) to leverage JAX s considerable expertise and infrastructure to maintain and distribute MD mouse and information resources to the scientific community. In Aim 2 we are developing novel DMD transgenic mice, which model patients receiving successful exon-skipping therapies. We propose to address the fundamental, but often overlooked question related to the functionality of resulting Dystrophin molecules containing in-frame deletions that are expected to arise by successful treatment of patient mutations. Our transgenic experiments will model the best-case-scenario outcome for AO-mediated therapy in which one assumes that a particular compound is capable of 100% effective exon-skipping to restore the reading frame. In Aim 3, we are generating congenic mdx mice to better model the symptoms of the human disease and to identify genetic modifiers that can alter disease onset and severity. In Aim 4, Dr. Nagaraju at CNMC is carrying out preclinical studies with three promising therapeutic compounds (GW501516, AICAR and Dantrolene) using key models developed at JAX. Overall, this program will greatly expand the accessibility and availability of mouse model resources for MD translational research and therapeutic development.
Keywords Chemotherapy
Clinical medicine
Diseases
Genetic engineering
Hypotheses
Information systems
Infrastructure
Medical services
Muscles
Muscular dystrophy
Signs and symptoms
Test and evaluation
Therapy
Transcription(Genetics)

 
Source Agency Non Paid ADAS
NTIS Subject Category 57E - Clinical Medicine
Corporate Author Jackson Lab., Bar Harbor, ME.
Document Type Technical report
Title Note Annual rept. 1 Mar 2011-30 Apr 2012.
NTIS Issue Number 1303
Contract Number W81XWH-11-1-0330

Science and Technology Highlights

See a sampling of the latest scientific, technical and engineering information from NTIS in the NTIS Technical Reports Newsletter

Acrobat Reader Mobile    Acrobat Reader